ANTICANCER COMPOSITIONS

The present invention concerns pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but...

Full description

Saved in:
Bibliographic Details
Main Authors MENSCH, Jurgen, BERTELS, Johny
Format Patent
LanguageEnglish
Published 29.11.2018
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract The present invention concerns pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMCAS, a poly(meth)acrylate copolymer, and mixtures thereof. In one aspect, these formulations comprise a granulate of abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMC AS, a poly(meth)acrylate copolymer, and mixtures thereof.
AbstractList The present invention concerns pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMCAS, a poly(meth)acrylate copolymer, and mixtures thereof. In one aspect, these formulations comprise a granulate of abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMC AS, a poly(meth)acrylate copolymer, and mixtures thereof.
Author BERTELS, Johny
MENSCH, Jurgen
Author_xml – fullname: MENSCH, Jurgen
– fullname: BERTELS, Johny
BookMark eNrjYmDJy89L5WQQd_QL8XR29HN2DVJw9vcN8A_2DPH09wvmYWBNS8wpTuWF0twMKm6uIc4euqkF-fGpxQWJyal5qSXxwe6GhkYGhhYGlmYWBoGOxkQqAwB8TyLd
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID SG11201809680QA
GroupedDBID EVB
ID FETCH-epo_espacenet_SG11201809680QA3
IEDL.DBID EVB
IngestDate Fri Jul 19 15:11:56 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_SG11201809680QA3
Notes Application Number: SG20181109680Q
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181129&DB=EPODOC&CC=SG&NR=11201809680QA
ParticipantIDs epo_espacenet_SG11201809680QA
PublicationCentury 2000
PublicationDate 20181129
PublicationDateYYYYMMDD 2018-11-29
PublicationDate_xml – month: 11
  year: 2018
  text: 20181129
  day: 29
PublicationDecade 2010
PublicationYear 2018
RelatedCompanies ARAGON PHARMACEUTICALS, INC
RelatedCompanies_xml – name: ARAGON PHARMACEUTICALS, INC
Score 3.1751544
Snippet The present invention concerns pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to a mammal, in particular a human,...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title ANTICANCER COMPOSITIONS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181129&DB=EPODOC&locale=&CC=SG&NR=11201809680QA
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSUo0NzMxN07TNUs2S9U1MUlJ1k1MNTHVNUgzSAU2HxKBaRo0o-vrZ-YRauIVYRrBxJAL2wsDPie0HHw4IjBHJQPzewm4vC5ADGK5gNdWFusnZQKF8u3dQmxd1KC9Y2B1Bay_1FycbF0D_F38ndWcnW2D3dX8gmyB4uCjqswsDAIdmRlYgS1pc1CGcA1zAm1MKUCuVdwEGdgCgAbmlQgxMKXmCTNwOsMuXxNm4PCFznkDmdDsVyzCIO7oFwK6otHZNUjB2d83wD_YE7wLWJRBxc01xNlDF2hDPNxH8cHuKO4xFmNgAXb2UyUYFIxNUiyBNbxBmmEasK1gYWqRZGCZmJyUlGZhkGZpnmQhySCL1ygpAvLSDFwgHmg3nZGlDANLSVFpqiywWi1JkgMHBgCLJ3dU
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LT8MwDLbGQIwbjDcMdph6qyg0fR0qtKXtOlgfbAXtVjVdKnFgTKyIv48bdTwucItsyXkozhfHsQ3QY5mhE0MtZD3XuUzIPJczTjRZKRSO14cM93Tl0Q1C3X8kdzNt1oCXdSyMyBP6IZIjokblqO-lOK-X349Yjvhbubpiz0h6vfUS25Fq6xjhCvFLcga2G0dORCVK7elQCic20kWqKt1UHvobsIlDMCqFcJ8GVWDK8ieqeLuwFaPARbkHDb5oQ4uui6-1YTuofd7YrNVvtQ9H_TCpSjRSd9KlURBH05GIAj6Anucm1Jexh_RrRul0-Gs86iE00djnx9BVydxChFeK6wLvCqZmMsXKcsYKUyksg5kn0PlT1Ok__Eto-UkwTsej8P4MdipOFVl3Y51Ds3x75x2E2JJdiIX5BE4Uekc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANTICANCER+COMPOSITIONS&rft.inventor=MENSCH%2C+Jurgen&rft.inventor=BERTELS%2C+Johny&rft.date=2018-11-29&rft.externalDBID=A&rft.externalDocID=SG11201809680QA